Ondansetron
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Antiemetics | Ondansetron | 8mg PO/IV Q8H | Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 293.36 | <5 | 2.5-5.5 | unchanged | 70-76% | 2 | N/A | N/A |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2013 Feb 06 [cited 2013 Feb 06]; Available from: URL: http://www.drugbank.ca/
- Ondansetron. In: Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc,; [updated 02/06/13; accessed 02/06/13].